Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 9;22(1):1317.
doi: 10.1186/s12889-022-13528-8.

"It comes altogether as one:" perceptions of analytical treatment interruptions and partner protections among racial, ethnic, sex and gender diverse HIV serodifferent couples in the United States

Affiliations

"It comes altogether as one:" perceptions of analytical treatment interruptions and partner protections among racial, ethnic, sex and gender diverse HIV serodifferent couples in the United States

Danielle M Campbell et al. BMC Public Health. .

Abstract

Background: Most HIV cure-related studies involve interrupting antiretroviral treatment to assess the efficacy of pharmacologic interventions - also known as analytical treatment interruptions (ATIs). ATIs imply the risk of passing HIV to sexual partners due to the loss of undetectable HIV status. There has been a notable lack of attention paid to perceptions of ATIs among racial, ethnic, sex and gender minorities, and HIV serodifferent couples. These populations are among those most impacted by HIV in the United States. Future HIV cure research paradigms should equitably include considerations from these groups.

Methods: From August - October 2020, we conducted in-depth interviews with 10 racial, ethnic, sex, and gender minority HIV serodifferent couples in geographically diverse regions of the United States to understand their perspectives about ATIs and partner protection measures to prevent secondary HIV transmissions because of participation in ATI studies. We used framework analysis to analyze the qualitative data.

Results: Of the 10 couples recruited, four identified as a gay couple, two as a gay and bisexual couple, two as a heterosexual couple, one as a gay and queer couple, and one as a queer couple. We found that HIV serodifferent couples in our study viewed ATIs as contradicting HIV treatment adherence messages. Couples expressed discomfort around ATIs in HIV cure research. They were concerned with the return of HIV detectability and worried ATIs might result in secondary HIV transmission. Participants were strongly in favor of using a range of partner protection measures during ATIs that included PrEP, HIV risk reduction counseling, and alternatives for penetrative sex practices. Couples also recommended that sex partners be consulted or involved as part of ATI trials.

Conclusions: Our findings highlight new potential opportunities and strategies to mitigate risk of HIV transmission during ATIs among key groups historically under-represented in HIV cure research. Findings also underscore the relational aspects of ATI trials. We provide preliminary considerations for planning ATI trials with diverse HIV serodifferent partners. Future studies should continue to explore these issues among other types of partnerships, cultures, and socio-cultural settings.

Keywords: Analytical treatment interruptions; Couples; HIV cure research; HIV serodifferent partners; Partner protection measures; Racial and ethnic minorities; Sexual and gender minorities; Socio-behavioral research.

PubMed Disclaimer

Conflict of interest statement

K.D. has received funding from Gilead Sciences, Inc. and Merck & Co., Inc. that is not directly related to this study. All other authors declare that they have no competing interests.

References

    1. Cohen M, Chen Y, McCauley M, Gamble T, Hosseinipour M, Al E. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016;375(9):830–839. doi: 10.1056/NEJMoa1600693. - DOI - PMC - PubMed
    1. Margolis DM. Eradication therapies for HIV infection: time to begin again. AIDS Res Hum Retrovir. 2011;27(4):347–353. doi: 10.1089/aid.2011.0017. - DOI - PMC - PubMed
    1. Deeks SG, Archin N, Cannon P, Collins S, Jones RB, de Jong MA, et al. Research priorities for an HIV cure: international AIDS society global scientific strategy 2021. Nat Med. 2021;27:2085–2098. doi: 10.1038/s41591-021-01590-5. - DOI - PubMed
    1. Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, et al. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials — report of a consensus meeting. Lancet HIV. 2019;6(4):e259–e268. doi: 10.1016/S2352-3018(19)30052-9. - DOI - PMC - PubMed
    1. TAG . Research Toward a Cure Trials. 2021.

Publication types